Fig. 3
From: MZ1 co-operates with trastuzumab in HER2 positive breast cancer
In vivo analysis of xenografted tumors treated with MZ1, trastuzumab or MZ1-trastuzumab. a Graphical representation of the tumor volumes (mm3) of BT474-derived tumors treated with either MZ1 (10 mg/kg), trastuzumab (30 mg/Kg) or MZ1-trastuzumab combination along the days of treatment. Mean of tumor volume ± SEM is indicated. b Western blot showing the expression levels of BRD4, pERBB2 and ERBB2 in tumors treated with MZ1, trastuzumab, combination or left untreated. *p < 0.05; **p < 0.01 (t-test one-tail, unpaired)